Loading…

Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study

Giant-cell arteritis (GCA) is the most common type of vasculitis in the elderly and is associated with high risks of visual loss and recurrence. Owing to its rarity in Asian populations, the current clinical interventions for these patients are not well known. Here we aimed to characterize the curre...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical neurology (Seoul, Korea) 2024, 20(3), , pp.306-314
Main Authors: Kang, Mi-Kyoung, Hong, Yooha, Kim, Yoo Hwan, Park, Hong-Kyun, Kim, Soo-Kyoung, Sohn, Jong-Hee, Kim, Jiyoung, Kwon, Ki-Han, Cho, Soo-Jin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c379t-aedcf1d2b35f63e304f93e13f6e4f0cf101fd7d7b8f05e10b9bb91ad43499383
container_end_page 314
container_issue 3
container_start_page 306
container_title Journal of clinical neurology (Seoul, Korea)
container_volume 20
creator Kang, Mi-Kyoung
Hong, Yooha
Kim, Yoo Hwan
Park, Hong-Kyun
Kim, Soo-Kyoung
Sohn, Jong-Hee
Kim, Jiyoung
Kwon, Ki-Han
Cho, Soo-Jin
description Giant-cell arteritis (GCA) is the most common type of vasculitis in the elderly and is associated with high risks of visual loss and recurrence. Owing to its rarity in Asian populations, the current clinical interventions for these patients are not well known. Here we aimed to characterize the current management status of patients with GCA using Korean multicenter data. This retrospective study analyzed medical records of patients with GCA at six Korean university hospitals from February 2009 to November 2022. GCA had originally been diagnosed based on the 1990 American College of Rheumatology (ACR) criteria, and cases were selected for inclusion in this study based on the 2022 ACR/European Alliance of Associations for Rheumatology criteria. We evaluated treatments, follow-up periods, and outcomes (relapse, remission, and adverse drug reactions) in patients with GCA with or without arteritic anterior ischemic optic neuropathy (AAION). This study analyzed 18 patients with a median age of 75.5 years that included 12 females (66.7%). Seven patients (38.8%) had AAION. All patients initially received prednisolone treatment, while four (22.2%) underwent adjuvant treatment with methotrexate and azathioprine during prednisolone tapering. During the median follow-up of 3.5 months (interquartile range: 2.0-23.2 months), 4 patients (22.2%) had prednisolone-related adverse reactions, 2 (11.1%) relapsed, and 13 (72.3%) dropped out. Nine patients (50.0%) experienced remission, with this being sustained in four (36.4%). This study observed high dropout rates and short follow-ups. Adverse effects of prednisolone were common, and relapses occurred in approximately one-tenth of Korean patients with GCA. Thus, optimizing GCA treatment necessitates regular monitoring and long-term follow-up.
doi_str_mv 10.3988/jcn.2023.0169
format article
fullrecord <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_10426795</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3040320895</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-aedcf1d2b35f63e304f93e13f6e4f0cf101fd7d7b8f05e10b9bb91ad43499383</originalsourceid><addsrcrecordid>eNpVkUFP3DAQhS3UCraUI9fKxwqR7dhOHJsLWm0LRQIh0eWK5SQ2NWTjxXao-Pf17lJET3OYN-89zYfQIYEpk0J8e2iHKQXKpkC43EETClAVFRD2AU1IzUTBK8H30KcYHwB4DYLsoj0mOK0p5RN0993p-8FHF4_xIhidlmZIx1gPHT7zfe__FLcr7C0-d3pIxdz0PZ6FZIJLLp7gGb4xKfi4Mm1yzwZfjX1ybXYwAf9KY_fyGX20uo_m4HXuo8XZj8X8Z3F5fX4xn10WLatlKrTpWks62rDKcmYYlFYyQ5jlprSQV0BsV3d1IyxUhkAjm0YS3ZWslJIJto-OtrZDsOqxdcprt5n3Xj0GNbtZXCgCJeW1rLL4dCtejc0yB-e6QfdqFdxSh5fN6f-bwf3ORs-KEKg5ETw7fH11CP5pNDGppYtt_o0ejB-jyv2BURCbsGIrbfObYjD2LYeAWgNUGaBaA1RrgFn_5X25N_U_YuwvNd6Xhg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3040320895</pqid></control><display><type>article</type><title>Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study</title><source>PubMed Central</source><creator>Kang, Mi-Kyoung ; Hong, Yooha ; Kim, Yoo Hwan ; Park, Hong-Kyun ; Kim, Soo-Kyoung ; Sohn, Jong-Hee ; Kim, Jiyoung ; Kwon, Ki-Han ; Cho, Soo-Jin</creator><creatorcontrib>Kang, Mi-Kyoung ; Hong, Yooha ; Kim, Yoo Hwan ; Park, Hong-Kyun ; Kim, Soo-Kyoung ; Sohn, Jong-Hee ; Kim, Jiyoung ; Kwon, Ki-Han ; Cho, Soo-Jin</creatorcontrib><description>Giant-cell arteritis (GCA) is the most common type of vasculitis in the elderly and is associated with high risks of visual loss and recurrence. Owing to its rarity in Asian populations, the current clinical interventions for these patients are not well known. Here we aimed to characterize the current management status of patients with GCA using Korean multicenter data. This retrospective study analyzed medical records of patients with GCA at six Korean university hospitals from February 2009 to November 2022. GCA had originally been diagnosed based on the 1990 American College of Rheumatology (ACR) criteria, and cases were selected for inclusion in this study based on the 2022 ACR/European Alliance of Associations for Rheumatology criteria. We evaluated treatments, follow-up periods, and outcomes (relapse, remission, and adverse drug reactions) in patients with GCA with or without arteritic anterior ischemic optic neuropathy (AAION). This study analyzed 18 patients with a median age of 75.5 years that included 12 females (66.7%). Seven patients (38.8%) had AAION. All patients initially received prednisolone treatment, while four (22.2%) underwent adjuvant treatment with methotrexate and azathioprine during prednisolone tapering. During the median follow-up of 3.5 months (interquartile range: 2.0-23.2 months), 4 patients (22.2%) had prednisolone-related adverse reactions, 2 (11.1%) relapsed, and 13 (72.3%) dropped out. Nine patients (50.0%) experienced remission, with this being sustained in four (36.4%). This study observed high dropout rates and short follow-ups. Adverse effects of prednisolone were common, and relapses occurred in approximately one-tenth of Korean patients with GCA. Thus, optimizing GCA treatment necessitates regular monitoring and long-term follow-up.</description><identifier>ISSN: 1738-6586</identifier><identifier>EISSN: 2005-5013</identifier><identifier>DOI: 10.3988/jcn.2023.0169</identifier><identifier>PMID: 38627226</identifier><language>eng</language><publisher>Korea (South): Korean Neurological Association</publisher><subject>Original ; 신경과학</subject><ispartof>Journal of Clinical Neurology, 2024, 20(3), , pp.306-314</ispartof><rights>Copyright © 2024 Korean Neurological Association.</rights><rights>Copyright © 2024 Korean Neurological Association 2024 Korean Neurological Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c379t-aedcf1d2b35f63e304f93e13f6e4f0cf101fd7d7b8f05e10b9bb91ad43499383</cites><orcidid>0000-0002-8693-2831 ; 0000-0001-6399-2236 ; 0000-0002-9532-5769 ; 0000-0002-8120-2469 ; 0000-0003-2656-9222 ; 0000-0001-7592-2921 ; 0000-0002-7230-4033 ; 0000-0002-4053-3763 ; 0000-0001-7260-3984</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076186/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076186/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38627226$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003073222$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Kang, Mi-Kyoung</creatorcontrib><creatorcontrib>Hong, Yooha</creatorcontrib><creatorcontrib>Kim, Yoo Hwan</creatorcontrib><creatorcontrib>Park, Hong-Kyun</creatorcontrib><creatorcontrib>Kim, Soo-Kyoung</creatorcontrib><creatorcontrib>Sohn, Jong-Hee</creatorcontrib><creatorcontrib>Kim, Jiyoung</creatorcontrib><creatorcontrib>Kwon, Ki-Han</creatorcontrib><creatorcontrib>Cho, Soo-Jin</creatorcontrib><title>Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study</title><title>Journal of clinical neurology (Seoul, Korea)</title><addtitle>J Clin Neurol</addtitle><description>Giant-cell arteritis (GCA) is the most common type of vasculitis in the elderly and is associated with high risks of visual loss and recurrence. Owing to its rarity in Asian populations, the current clinical interventions for these patients are not well known. Here we aimed to characterize the current management status of patients with GCA using Korean multicenter data. This retrospective study analyzed medical records of patients with GCA at six Korean university hospitals from February 2009 to November 2022. GCA had originally been diagnosed based on the 1990 American College of Rheumatology (ACR) criteria, and cases were selected for inclusion in this study based on the 2022 ACR/European Alliance of Associations for Rheumatology criteria. We evaluated treatments, follow-up periods, and outcomes (relapse, remission, and adverse drug reactions) in patients with GCA with or without arteritic anterior ischemic optic neuropathy (AAION). This study analyzed 18 patients with a median age of 75.5 years that included 12 females (66.7%). Seven patients (38.8%) had AAION. All patients initially received prednisolone treatment, while four (22.2%) underwent adjuvant treatment with methotrexate and azathioprine during prednisolone tapering. During the median follow-up of 3.5 months (interquartile range: 2.0-23.2 months), 4 patients (22.2%) had prednisolone-related adverse reactions, 2 (11.1%) relapsed, and 13 (72.3%) dropped out. Nine patients (50.0%) experienced remission, with this being sustained in four (36.4%). This study observed high dropout rates and short follow-ups. Adverse effects of prednisolone were common, and relapses occurred in approximately one-tenth of Korean patients with GCA. Thus, optimizing GCA treatment necessitates regular monitoring and long-term follow-up.</description><subject>Original</subject><subject>신경과학</subject><issn>1738-6586</issn><issn>2005-5013</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkUFP3DAQhS3UCraUI9fKxwqR7dhOHJsLWm0LRQIh0eWK5SQ2NWTjxXao-Pf17lJET3OYN-89zYfQIYEpk0J8e2iHKQXKpkC43EETClAVFRD2AU1IzUTBK8H30KcYHwB4DYLsoj0mOK0p5RN0993p-8FHF4_xIhidlmZIx1gPHT7zfe__FLcr7C0-d3pIxdz0PZ6FZIJLLp7gGb4xKfi4Mm1yzwZfjX1ybXYwAf9KY_fyGX20uo_m4HXuo8XZj8X8Z3F5fX4xn10WLatlKrTpWks62rDKcmYYlFYyQ5jlprSQV0BsV3d1IyxUhkAjm0YS3ZWslJIJto-OtrZDsOqxdcprt5n3Xj0GNbtZXCgCJeW1rLL4dCtejc0yB-e6QfdqFdxSh5fN6f-bwf3ORs-KEKg5ETw7fH11CP5pNDGppYtt_o0ejB-jyv2BURCbsGIrbfObYjD2LYeAWgNUGaBaA1RrgFn_5X25N_U_YuwvNd6Xhg</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Kang, Mi-Kyoung</creator><creator>Hong, Yooha</creator><creator>Kim, Yoo Hwan</creator><creator>Park, Hong-Kyun</creator><creator>Kim, Soo-Kyoung</creator><creator>Sohn, Jong-Hee</creator><creator>Kim, Jiyoung</creator><creator>Kwon, Ki-Han</creator><creator>Cho, Soo-Jin</creator><general>Korean Neurological Association</general><general>대한신경과학회</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0002-8693-2831</orcidid><orcidid>https://orcid.org/0000-0001-6399-2236</orcidid><orcidid>https://orcid.org/0000-0002-9532-5769</orcidid><orcidid>https://orcid.org/0000-0002-8120-2469</orcidid><orcidid>https://orcid.org/0000-0003-2656-9222</orcidid><orcidid>https://orcid.org/0000-0001-7592-2921</orcidid><orcidid>https://orcid.org/0000-0002-7230-4033</orcidid><orcidid>https://orcid.org/0000-0002-4053-3763</orcidid><orcidid>https://orcid.org/0000-0001-7260-3984</orcidid></search><sort><creationdate>20240501</creationdate><title>Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study</title><author>Kang, Mi-Kyoung ; Hong, Yooha ; Kim, Yoo Hwan ; Park, Hong-Kyun ; Kim, Soo-Kyoung ; Sohn, Jong-Hee ; Kim, Jiyoung ; Kwon, Ki-Han ; Cho, Soo-Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-aedcf1d2b35f63e304f93e13f6e4f0cf101fd7d7b8f05e10b9bb91ad43499383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Original</topic><topic>신경과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Mi-Kyoung</creatorcontrib><creatorcontrib>Hong, Yooha</creatorcontrib><creatorcontrib>Kim, Yoo Hwan</creatorcontrib><creatorcontrib>Park, Hong-Kyun</creatorcontrib><creatorcontrib>Kim, Soo-Kyoung</creatorcontrib><creatorcontrib>Sohn, Jong-Hee</creatorcontrib><creatorcontrib>Kim, Jiyoung</creatorcontrib><creatorcontrib>Kwon, Ki-Han</creatorcontrib><creatorcontrib>Cho, Soo-Jin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Journal of clinical neurology (Seoul, Korea)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Mi-Kyoung</au><au>Hong, Yooha</au><au>Kim, Yoo Hwan</au><au>Park, Hong-Kyun</au><au>Kim, Soo-Kyoung</au><au>Sohn, Jong-Hee</au><au>Kim, Jiyoung</au><au>Kwon, Ki-Han</au><au>Cho, Soo-Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study</atitle><jtitle>Journal of clinical neurology (Seoul, Korea)</jtitle><addtitle>J Clin Neurol</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>20</volume><issue>3</issue><spage>306</spage><epage>314</epage><pages>306-314</pages><issn>1738-6586</issn><eissn>2005-5013</eissn><abstract>Giant-cell arteritis (GCA) is the most common type of vasculitis in the elderly and is associated with high risks of visual loss and recurrence. Owing to its rarity in Asian populations, the current clinical interventions for these patients are not well known. Here we aimed to characterize the current management status of patients with GCA using Korean multicenter data. This retrospective study analyzed medical records of patients with GCA at six Korean university hospitals from February 2009 to November 2022. GCA had originally been diagnosed based on the 1990 American College of Rheumatology (ACR) criteria, and cases were selected for inclusion in this study based on the 2022 ACR/European Alliance of Associations for Rheumatology criteria. We evaluated treatments, follow-up periods, and outcomes (relapse, remission, and adverse drug reactions) in patients with GCA with or without arteritic anterior ischemic optic neuropathy (AAION). This study analyzed 18 patients with a median age of 75.5 years that included 12 females (66.7%). Seven patients (38.8%) had AAION. All patients initially received prednisolone treatment, while four (22.2%) underwent adjuvant treatment with methotrexate and azathioprine during prednisolone tapering. During the median follow-up of 3.5 months (interquartile range: 2.0-23.2 months), 4 patients (22.2%) had prednisolone-related adverse reactions, 2 (11.1%) relapsed, and 13 (72.3%) dropped out. Nine patients (50.0%) experienced remission, with this being sustained in four (36.4%). This study observed high dropout rates and short follow-ups. Adverse effects of prednisolone were common, and relapses occurred in approximately one-tenth of Korean patients with GCA. Thus, optimizing GCA treatment necessitates regular monitoring and long-term follow-up.</abstract><cop>Korea (South)</cop><pub>Korean Neurological Association</pub><pmid>38627226</pmid><doi>10.3988/jcn.2023.0169</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8693-2831</orcidid><orcidid>https://orcid.org/0000-0001-6399-2236</orcidid><orcidid>https://orcid.org/0000-0002-9532-5769</orcidid><orcidid>https://orcid.org/0000-0002-8120-2469</orcidid><orcidid>https://orcid.org/0000-0003-2656-9222</orcidid><orcidid>https://orcid.org/0000-0001-7592-2921</orcidid><orcidid>https://orcid.org/0000-0002-7230-4033</orcidid><orcidid>https://orcid.org/0000-0002-4053-3763</orcidid><orcidid>https://orcid.org/0000-0001-7260-3984</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1738-6586
ispartof Journal of Clinical Neurology, 2024, 20(3), , pp.306-314
issn 1738-6586
2005-5013
language eng
recordid cdi_nrf_kci_oai_kci_go_kr_ARTI_10426795
source PubMed Central
subjects Original
신경과학
title Diagnosis, Treatment, and Follow-Up of Giant-Cell Arteritis: A Retrospective Multicenter Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A18%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnosis,%20Treatment,%20and%20Follow-Up%20of%20Giant-Cell%20Arteritis:%20A%20Retrospective%20Multicenter%20Study&rft.jtitle=Journal%20of%20clinical%20neurology%20(Seoul,%20Korea)&rft.au=Kang,%20Mi-Kyoung&rft.date=2024-05-01&rft.volume=20&rft.issue=3&rft.spage=306&rft.epage=314&rft.pages=306-314&rft.issn=1738-6586&rft.eissn=2005-5013&rft_id=info:doi/10.3988/jcn.2023.0169&rft_dat=%3Cproquest_nrf_k%3E3040320895%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c379t-aedcf1d2b35f63e304f93e13f6e4f0cf101fd7d7b8f05e10b9bb91ad43499383%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3040320895&rft_id=info:pmid/38627226&rfr_iscdi=true